Summary
Amgen Inc. (AMGN) filed an 8-K on January 23, 2013, to report its unaudited financial results for the fourth quarter and full year ended December 31, 2012. The report primarily details the company's use of non-GAAP financial measures to provide investors with a supplemental view of its operational performance and financial condition, alongside its GAAP results. These non-GAAP measures adjust for various items including cost-saving initiatives, stock option expensing, acquisition-related expenses, amortization of acquired intangible assets, contingent consideration, legal proceedings, non-cash interest on convertible notes, and tax effects. Amgen emphasizes that these non-GAAP figures are not a substitute for GAAP but are intended to facilitate a more comparable analysis of financial performance across different periods and against internally developed assets. The company also reported Free Cash Flow (FCF) as a non-GAAP measure to indicate liquidity.
Key Highlights
- 1Amgen reported its unaudited financial results for the fourth quarter and full year ended December 31, 2012.
- 2The company utilized non-GAAP financial measures to provide supplemental information to investors, alongside standard GAAP reporting.
- 3Key adjustments in non-GAAP measures include cost-saving initiatives, stock option expensing, acquisition-related expenses, and amortization of acquired product technology rights.
- 4Non-GAAP metrics are presented to offer a clearer view of operating performance and financial condition, facilitating comparisons across periods.
- 5Amgen also reported Free Cash Flow (FCF) as a non-GAAP metric to illustrate liquidity.
- 6The report indicates the company's ongoing efforts to improve cost efficiencies in its operations.
- 7The filing includes a press release dated January 23, 2013, as Exhibit 99.1, which contains the detailed financial results and non-GAAP reconciliations.